AIM Immunotech Inc. Form 8-K Summary
Business Context and Reporting Period
Company: AIM Immunotech Inc.
Filing Date: May 8, 2026 (Event Date)
Reporting Period: Current Report on Form 8-K
Principal Office: Ocala, FL
This filing reports the closing of an unregistered sale of equity securities (Item 3.02) involving a warrant exercise inducement transaction.
Key Financial Metrics
The filing details a specific capital raise event rather than periodic financial performance. Key figures include:
- Gross Proceeds: Approximately $3.6 million received from the exercise of existing warrants.
- Shares Issued: 7,451,920 shares of Common Stock issued upon exercise.
- Exercise Price: Reduced exercise price of $0.48 per share.
- Transaction Costs:
- Placement Agent Cash Fee: Approximately $285,000 (8.0% of gross proceeds).
- Expense Reimbursement: $50,000.
- Management Fee: Approximately $26,000 (0.75% of gross proceeds).
- Debt and Liquidity: The filing text does not provide clear values for total debt, cash flow, or overall liquidity positions outside of the proceeds from this specific transaction.
Material Changes and Transaction Details
The Company executed an "Inducement Transaction" to encourage holders of existing warrants (Classes A through F) to exercise their rights. Material terms include:
- Inducement Warrants: The Company issued new Class H warrants to purchase up to 14,903,840 shares of Common Stock.
- Inducement Warrant Terms: Exercise price of $0.60 per share; exercisable for five years following stockholder approval.
- Placement Agent Warrants: Ladenburg Thalmann & Co. Inc. received warrants to purchase 6.0% of the shares issued in the transaction (Placement Agent Warrant Shares).
- Placement Agent Warrant Terms: Exercise price equal to 125% of the reduced exercise price ($0.60); exercisable for five years from issuance; includes piggyback registration rights.
Guidance, Risks, and Contingencies
Regulatory Status: The Inducement Warrants and Placement Agent Warrants were issued pursuant to the Section 4(a)(2) exemption from registration under the Securities Act of 1933. These securities are not registered and may not be offered or sold in the United States absent registration or an applicable exemption.
Stockholder Approval: The exercisability of the Inducement Warrants is contingent upon a "Stockholder Approval Date" as defined in the Inducement Letter.
Management Commentary: The filing does not contain forward-looking guidance, outlook statements, or management commentary regarding future operations beyond the description of the transaction.
Investor Verification Checklist
- Verify the status of the "Stockholder Approval Date" required to make the new Class H Inducement Warrants exercisable.
- Confirm the dilution impact of the 14,903,840 new Inducement Warrants and the Placement Agent Warrants on existing shareholders.
- Review the full text of the Inducement Letter (not included in this summary) for specific conditions regarding the reduced exercise price.
- Check subsequent filings for the registration status of the Placement Agent Warrant Shares, as piggyback rights are triggered if no effective registration statement exists.